Why raising NHS spending on new drugs by 25% is the wrong decision – health economist's view

Rhiannon Tudor Edwards

School of Health Sciences

Press/Media: Expert Comment

Description

Comment on the fact that ministers will be setting the NICE cost-effectiveness threshold as of April 1st 2026, in order to comply with a trade deal with the US for new phrarmceuticals, and the implications for spending on prevention.

https://theconversation.com/why-raising-nhs-spending-on-new-drugs-by-25-is-the-wrong-decision-health-economists-view-273952

This was read by 2000+ people in the first week.

Period	5 Feb 2026

Media contributions

Title	Why raising NHS spending on new drugs by 25% is the wrong decision – health economist's view
Degree of recognition	International
Media name/outlet	The Conversation UK
Media type	Web
Country/Territory	United Kingdom
Date	5/02/26
Producer/Author	Rhiannon Tudor Edwards
URL	https://theconversation.com/why-raising-nhs-spending-on-new-drugs-by-25-is-the-wrong-decision-health-economists-view-273952
Persons	Rhiannon Tudor Edwards

View all 1

View less

Keywords

medicines health economics prevention Public Health NHS 10-year plan trade